2023
Prion Protein Complex with mGluR5 Mediates Amyloid-ß Synaptic Loss in Alzheimer’s Disease
Roseman G, Fu L, Strittmatter S. Prion Protein Complex with mGluR5 Mediates Amyloid-ß Synaptic Loss in Alzheimer’s Disease. 2023, 467-481. DOI: 10.1007/978-3-031-20565-1_22.ChaptersAlzheimer's diseaseMouse modelAD transgenic mouse modelLong-term potentiation impairmentPrimary histopathological featureAD mouse modelAmyloid-beta plaquesTransgenic mouse modelPotential therapeutic targetSynaptic lossHistopathological featuresAD pathophysiologyNeuronal dysfunctionSynapse densityCognitive dysfunctionNeurofibrillary tanglesTherapeutic targetMemory deficitsCellular prion proteinMGluR5DiseaseCell death characteristicCommon formSynaptotoxicityDysfunction
2022
PET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging
Toyonaga T, Fesharaki-Zadeh A, Strittmatter SM, Carson RE, Cai Z. PET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging. Frontiers In Neuroscience 2022, 16: 787404. PMID: 35345546, PMCID: PMC8957200, DOI: 10.3389/fnins.2022.787404.Peer-Reviewed Original ResearchAnimal modelsPET imaging studiesPET imagingImaging studiesSynaptic vesicle glycoprotein 2ADisease animal modelsOngoing clinical investigationsDifferent injection routesSynaptic densityClinical investigationPharmacological effectsRodent brainNovel interventionsInjection routeNeurodegenerative disordersNeuropsychiatric diseasesPET studiesBrainMultiple diseasesPET centersDiseaseInjectable volumeImagingSmaller brainsPET
2019
Rescue of Transgenic Alzheimer’s Pathophysiology by Polymeric Cellular Prion Protein Antagonists
Gunther EC, Smith LM, Kostylev MA, Cox TO, Kaufman AC, Lee S, Folta-Stogniew E, Maynard GD, Um JW, Stagi M, Heiss JK, Stoner A, Noble GP, Takahashi H, Haas LT, Schneekloth JS, Merkel J, Teran C, Naderi Z, Supattapone S, Strittmatter SM. Rescue of Transgenic Alzheimer’s Pathophysiology by Polymeric Cellular Prion Protein Antagonists. Cell Reports 2019, 26: 145-158.e8. PMID: 30605671, PMCID: PMC6358723, DOI: 10.1016/j.celrep.2018.12.021.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseOligomeric β-amyloid peptideAPPswe/PS1ΔE9 transgenic miceEffective brain concentrationsPotential therapeutic approachΒ-amyloid peptideBrain concentrationsSynapse lossTherapeutic approachesAlzheimer's pathophysiologyTransgenic miceScN2a cellsMemory deficitsCellular prion proteinPathophysiologyTransmissible spongiformAβOsProtein antagonistLow nanomolar affinityDiseasePrPPrion proteinNanomolar affinitySupAntagonist
2017
Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model
Smith LM, Zhu R, Strittmatter SM. Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model. Neuropharmacology 2017, 130: 54-61. PMID: 29191754, PMCID: PMC5743608, DOI: 10.1016/j.neuropharm.2017.11.042.Peer-Reviewed Original ResearchConceptsAlzheimer's modelDisease-modifying effectsDisease-modifying therapiesMouse Alzheimer’s modelsTherapy withdrawalAPPswe/Investigational agentsSynapse densityDrug washoutTransgenic modelAlzheimer's diseasePersistent benefitsPersistent improvementSaracatinibFyn inhibitorMemantineLoss of benefitDiseaseSpatial memoryMemory functionWashoutTherapySymptomsMiceWeeksChapter Thirteen Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5
Brody AH, Strittmatter SM. Chapter Thirteen Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5. Advances In Pharmacology 2017, 82: 293-323. PMID: 29413525, PMCID: PMC5835229, DOI: 10.1016/bs.apha.2017.09.007.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseNovel potential therapeutic targetDisease-modifying AD therapiesPotential therapeutic targetAmyloid-beta oligomersPrion proteinSynapse lossTau pathologySynaptic dysfunctionAD symptomsSynaptic damageAD pathophysiologyNeuronal dysfunctionSynaptic toxicityDisease progressionAD progressionAD therapyMemory dysfunctionTherapeutic targetCellular prion proteinBeta oligomersDysfunctionDiseaseGlobal health crisisMGluR5
2016
Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity
Smith LM, Strittmatter SM. Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity. Cold Spring Harbor Perspectives In Medicine 2016, 7: a024075. PMID: 27940601, PMCID: PMC5411685, DOI: 10.1101/cshperspect.a024075.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseAβ oligomersSoluble Aβ oligomersFibrillary amyloidNeuronal impairmentSynaptic dysfunctionAD pathogenesisSynaptic toxicityAmyloid-β OligomersCellular prion proteinNeuronal cascadesFurther studiesCell surface proteinsDiseaseAβPrion proteinOligomer toxicityToxicityDysfunctionMolecular basisPathogenesisDementiaProteinPlaquesImpairmentChapter 8 Targeting Aβ Receptors to Modify Alzheimer’s Disease Progression
Haas L, Strittmatter S. Chapter 8 Targeting Aβ Receptors to Modify Alzheimer’s Disease Progression. 2016, 227-250. DOI: 10.1016/b978-0-12-802173-6.00008-3.Peer-Reviewed Original ResearchAlzheimer's diseaseDisease progressionIntervention sitesCourse of ADMetabotropic glutamate receptor 5Glutamate receptor 5Receptor-mediated mechanismAlzheimer's disease progressionHigh-affinity natureAD pathophysiologyReceptor mechanismsReceptor 5Preclinical successMGluR5 pathwayAβ receptorsCellular prion proteinSuch receptorsPathological processesDiseasePathophysiological signalsReceptorsPrion proteinSpecific pathwaysPathwayHigh affinity
2014
Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks
Strittmatter SM. Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks. Nature Medicine 2014, 20: 590-591. PMID: 24901567, PMCID: PMC4371131, DOI: 10.1038/nm.3595.Peer-Reviewed Original ResearchFyn kinase inhibition as a novel therapy for Alzheimer’s disease
Nygaard HB, van Dyck CH, Strittmatter SM. Fyn kinase inhibition as a novel therapy for Alzheimer’s disease. Alzheimer's Research & Therapy 2014, 6: 8. PMID: 24495408, PMCID: PMC3978417, DOI: 10.1186/alzrt238.Peer-Reviewed Original ResearchAlzheimer's diseasePathogenesis of ADTreatment of ADPhase Ib studyLate-stage clinical testingUnique therapeutic targetMajor pathologic hallmarkDevastating neurodegenerative disorderPathologic hallmarkNovel therapiesIb studyTherapeutic strategiesTherapeutic targetSmall molecule inhibitorsClinical testingTyrosine kinase FynCellular prion proteinNeurodegenerative disordersDiseaseAβ oligomersCell surface bindingMultisite studyHigh potencyMolecule inhibitorsTherapy
2013
Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease
Um JW, Strittmatter SM. Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. Prion 2013, 7: 37-41. PMID: 22987042, PMCID: PMC3609048, DOI: 10.4161/pri.22212.Peer-Reviewed Original ResearchConceptsCellular prion proteinPrion proteinSignal transduction downstreamTransduction downstreamAlzheimer's diseaseFyn kinaseFunctional consequencesAβ oligomersAmyloid-β OligomersNeuronal surfaceHigh-affinity receptorOligomer complexesAD-related phenotypesCentral roleProteinAD pathogenesisRecent evidencePrevalent causeTherapeutic interventionsFynKinaseOligomersPhenotypeDiseaseDownstream
2012
Role of Cellular Prion Protein in the Amyloid-β Oligomer Pathophysiology of Alzheimer’s Disease
Kaufman A, Strittmatter S. Role of Cellular Prion Protein in the Amyloid-β Oligomer Pathophysiology of Alzheimer’s Disease. 2012, 35-48. DOI: 10.1007/978-1-4614-5305-5_3.Peer-Reviewed Original ResearchAlzheimer's diseaseMouse modelCellular prion proteinPrimary histopathological featureAD mouse modelAmyloid-beta plaquesTransgenic mouse modelLong-term potentiationHistopathological featuresPrion proteinNeuronal dysfunctionNeurofibrillary tanglesMemory deficitsMemory lossDiseaseExact mechanismCommon formEssential mediatorPathophysiologyToxic effectsCell deathPrPCHigh-affinity binding partnerSynaptotoxicityDysfunctionVps10 Family Proteins and the Retromer Complex in Aging-Related Neurodegeneration and Diabetes
Lane RF, St George-Hyslop P, Hempstead BL, Small SA, Strittmatter SM, Gandy S. Vps10 Family Proteins and the Retromer Complex in Aging-Related Neurodegeneration and Diabetes. Journal Of Neuroscience 2012, 32: 14080-14086. PMID: 23055476, PMCID: PMC3576841, DOI: 10.1523/jneurosci.3359-12.2012.Peer-Reviewed Original ResearchConceptsBrain-derived neurotrophic factorType 2 diabetes mellitusNeurotrophic signaling pathwaysFrontotemporal lobar degenerationNon-neuronal cellsPathogenesis of neurodegenerationGenetic risk factorsBDNF levelsDiabetes mellitusFamily of receptorsNeurotrophic factorRisk factorsParkinson's diseaseTrk receptorsAcute responseAutosomal dominant formAlzheimer's diseaseNeurodegenerative diseasesDiseaseCell surface receptorsReceptorsSignaling pathwaysSurface receptorsPleiotropic functionsIntracellular responses
2009
β-amyloid oligomers and cellular prion protein in Alzheimer’s disease
Gunther EC, Strittmatter SM. β-amyloid oligomers and cellular prion protein in Alzheimer’s disease. Journal Of Molecular Medicine 2009, 88: 331-338. PMID: 19960174, PMCID: PMC2846635, DOI: 10.1007/s00109-009-0568-7.Peer-Reviewed Original ResearchConceptsCreutzfeldt-Jakob diseaseAβ oligomersDisease pathophysiologyCellular prion proteinProgression of ADAlzheimer's disease pathophysiologyΒ-amyloid oligomersΒ-amyloid peptidePrion proteinBrain slicesAlzheimer's diseaseSynaptic functionFunctional receptorsNeurodegenerative diseasesDiseasePotential mediatorsAβ assembliesReceptorsAβ monomersPrPCPathophysiologyNeurotoxicityPlaquesProgressionCellular Prion Protein Mediates the Toxicity of β-Amyloid Oligomers: Implications for Alzheimer Disease
Nygaard HB, Strittmatter SM. Cellular Prion Protein Mediates the Toxicity of β-Amyloid Oligomers: Implications for Alzheimer Disease. JAMA Neurology 2009, 66: 1325-1328. PMID: 19901162, PMCID: PMC2849161, DOI: 10.1001/archneurol.2009.223.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseCellular prion proteinPathogenesis of ADBeta-amyloid plaquesAge-related dementiaSoluble oligomeric assembliesPrion proteinPotential clinical implicationsBeta-amyloid oligomersΒ-amyloid oligomersHigh-affinity receptorCommon causeSynaptic plasticityTherapeutic interventionsClinical implicationsAbeta oligomersNovel targetRecent evidenceToxic effectsDiseasePathogenesisDementiaAbetaPlaquesBrainCellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 2009, 457: 1128-1132. PMID: 19242475, PMCID: PMC2748841, DOI: 10.1038/nature07761.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAmyloid beta-PeptidesAmyloid Precursor Protein SecretasesAmyloidosisAnimalsChlorocebus aethiopsCOS CellsHippocampusHumansLong-Term PotentiationMiceMice, Inbred C57BLNeuronal PlasticityNeuronsPeptide FragmentsPrionsProtein BindingProtein MultimerizationReceptors, Cell SurfaceSynapsesConceptsCellular prion protein PrPCPrion protein PrPCSoluble amyloid-β peptide (Aβ) oligomersAlzheimer's diseaseCellular prion proteinDisease pathologyPlasma membrane glycoproteinsCell surface receptorsHigh affinity cell surface receptorsAlzheimer's disease pathologySoluble Aβ oligomersLipid raftsInfectious prion diseasesUnexpected linkMechanistic basisMembrane glycoproteinsPrion proteinAmyloid-β peptide (Aβ) oligomersSynaptic plasticityPrion diseasesTherapeutic potentialDiseaseAβ oligomersCentral roleDeleterious effects
2007
Nogo receptor interacts with brain APP and Abeta to reduce pathologic changes in Alzheimer's transgenic mice.
Park JH, Strittmatter SM. Nogo receptor interacts with brain APP and Abeta to reduce pathologic changes in Alzheimer's transgenic mice. Current Alzheimer Research 2007, 4: 568-70. PMID: 18220524, PMCID: PMC2846284, DOI: 10.2174/156720507783018235.Peer-Reviewed Original ResearchConceptsTransgenic miceAlzheimer's diseasePlaque depositionAdult central nervous systemAlzheimer's transgenic miceNogo-66 receptorAmyloid β plaquesCentral nervous systemAxonal sproutingAβ accumulationΒ plaquesDystrophic neuritesPathologic changesNogo receptorNervous systemBrain APPDiseasePotential mechanistic basisMiceExpression increasesNGR modificationReceptorsNeurite responseNGRMechanistic basis
2002
Modulation of axonal regeneration in neurodegenerative disease
Strittmatter SM. Modulation of axonal regeneration in neurodegenerative disease. Journal Of Molecular Neuroscience 2002, 19: 117-121. PMID: 12212768, DOI: 10.1007/s12031-002-0021-7.Peer-Reviewed Original Research
1986
Parkinson's disease: Nigral receptor changes support peptidergic role in nigrostriatal modulation
Uhl G, Hackney G, Torchia M, Stranov V, Tourtellotte W, Whitehouse P, Tran V, Strittmatter S. Parkinson's disease: Nigral receptor changes support peptidergic role in nigrostriatal modulation. Annals Of Neurology 1986, 20: 194-203. PMID: 3019228, DOI: 10.1002/ana.410200204.Peer-Reviewed Original ResearchConceptsKappa-opiate receptorsIdiopathic Parkinson's diseaseNormal human brainNigrostriatal circuitryPeptidergic influencesReceptor changesSubstantia nigraMore modest reductionsSerotonin receptorsParkinson's diseaseBenzodiazepine receptorsAutoradiographic studyModest reductionReceptorsAngiotensinSomatostatinHuman brainDiseaseDopamineBenzodiazepines IPatientsNeurotensinSubtypesBrainNigra